{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"24.7","value":"1.6"},{"groupId":"OG001","lowerLimit":"1.1","upperLimit":"12.3","value":"2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"For participants who demonstrated a confirmed CR or PR per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. The DOR per RECIST 1.1 as assessed by BICR is presented for all participants who experienced a confirmed CR or PR.","dispersionType":"Full Range","groups":[{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG000","title":"Recurrent or Metastatic Cutaneous cSCC Cohort"},{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months).","id":"OG001","title":"Locally Advanced Unresectable cSCC Cohort"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all participants who received ≥1 dose of study treatment and had confirmed complete response or partial response.","reportingStatus":"POSTED","timeFrame":"Up to approximately 56 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}